Novo Nordisk A/s

Novo Industri A/s

Novo Nordisk Healthcare Ag

Novo Nordisk Pharmaceuticals, Inc.

Marie Johannessen

Ole Juul Nordfang

Jens Aas Jansen

Peter Tang

Allan Diedrichsen

The invention relates to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, said medicament being for subcutaneous, intramuscular or intradermal administration, and to the use of a Factor VIIa for the manufacture of a medicament for treatment of a condition affectable by Factor VIIa, wherein said medicament, when administered subcutaneously, intradermally or intramuscularly, shows a prolonged biological half-life.

Subcutaneous administration of coagulation factor VII

Coagulation factor Viia composition

Coagulation factor VIIa composition

Novel plasmin compositions, conditioned for labelling with technetium-99m by containing a pertechnetate reducing reagent, and plasmin admixed with a plasmin stabilizing agent. The novel compositions are particularly suited for the preparation of technetium-99m labelled plasmin used as a scintigraphic scanning agent for the detection of venous thrombosis.

Stabilized plasmin compositions and method for preparation thereof

Growing community of inventors

Birkerød, Denmark

Marie Johannessen